Skip to main content
. 2015 Mar 19;2015:793764. doi: 10.1155/2015/793764

Table 5.

Adverse effects during IFX therapy in CD patients.

Description of the events Number of patients (%)
Any adverse events 24 (22.6%)
Any serious adverse events 0
Infusion reactions 22 (20.8%)
 Fever or chills 7 (6.6%)
 Primarily chest pain 0
 Dyspnea 0
 Myalgia 4 (3.8%)
 Pruritus/rash 8 (7.5%)
 Nausea/vomiting 3 (2.8%)
 Anaphylaxis 0
 Seizures 0
 Hypotension 0
Infections 0
Hepatotoxicity 2 (1.9%)
Lupus-like syndrome 0
Psoriasiform rash 0
Deaths 0